Literature DB >> 18793032

Multiple sclerosis in the UK: service use, costs, quality of life and disability.

Paul McCrone1, Margaret Heslin, Martin Knapp, Paul Bull, Alan Thompson.   

Abstract

BACKGROUND: Multiple sclerosis (MS) is a chronic condition that affects quality of life (QOL), leads to disability and requires ongoing care inputs. Few studies have examined the impact of QOL, disability and demographic characteristics on treatment costs.
OBJECTIVE: To investigate the links between service use, costs, QOL and disability for people with MS.
METHODS: A cross-sectional study was conducted in people with MS who were members of the Multiple Sclerosis Society of Great Britain and Northern Ireland. A questionnaire, consisting of sociodemographic questions, the Client Service Receipt Inventory, EQ-5D and Guy's Neurological Disability Scale (GNDS), was sent to 4000 members of the Society. Service and lost employment costs were calculated. Regression models were developed to identify the participant characteristics that were associated with costs, QOL and disability. All costs are presented in year 2006-7 values.
RESULTS: Questionnaires were returned by 1942 members (48.9%). The mean (SD) EQ-5D QOL score was 0.41 (0.34), whilst the GNDS disability score was 20.8 (8.9). The mean (SD) service cost over the preceding 6 months was pound8397 ( pound10,404), and most of this (71.6%) was due to informal care. Only a small amount of cost (8.1%) was due to the use of disease-modifying drugs and drugs for spasticity. Lost employment costs amounted to a mean of pound4240. Higher costs were associated with higher levels of disability and lower levels of health-related QOL.
CONCLUSIONS: This study showed that MS participants had high levels of service use, and that QOL was low in comparison with other conditions. There were significant associations between costs, QOL and disability.

Entities:  

Mesh:

Year:  2008        PMID: 18793032     DOI: 10.2165/00019053-200826100-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  22 in total

Review 1.  A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models.

Authors:  R G Richards; F C Sampson; S M Beard; P Tappenden
Journal:  Health Technol Assess       Date:  2002       Impact factor: 4.014

2.  A comparison of two methods of collecting economic data in primary care.

Authors:  Anita Patel; Alison Rendu; Paul Moran; Morven Leese; Anthony Mann; Martin Knapp
Journal:  Fam Pract       Date:  2005-04-11       Impact factor: 2.267

3.  Health-related quality of life in a population-based sample of people with multiple sclerosis in Stockholm County.

Authors:  K Gottberg; U Einarsson; C Ytterberg; J de Pedro Cuesta; S Fredrikson; L von Koch; L Widén Holmqvist
Journal:  Mult Scler       Date:  2006-10       Impact factor: 6.312

4.  A cost-utility analysis of interferon beta for multiple sclerosis.

Authors:  D Parkin; P McNamee; A Jacoby; P Miller; S Thomas; D Bates
Journal:  Health Technol Assess       Date:  1998       Impact factor: 4.014

5.  A randomised controlled trial to evaluate the effectiveness and cost-effectiveness of counselling patients with chronic depression.

Authors:  S Simpson; R Corney; P Fitzgerald; J Beecham
Journal:  Health Technol Assess       Date:  2000       Impact factor: 4.014

6.  Cost-effectiveness of cognitive behavioural therapy, graded exercise and usual care for patients with chronic fatigue in primary care.

Authors:  P McCrone; L Ridsdale; L Darbishire; P Seed
Journal:  Psychol Med       Date:  2004-08       Impact factor: 7.723

7.  One year changes in disability in multiple sclerosis: neurological examination compared with patient self report.

Authors:  E L J Hoogervorst; M J Eikelenboom; B M J Uitdehaag; C H Polman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

8.  Reliable self-report of health service use by individuals with serious mental illness.

Authors:  Richard W Goldberg; Diana C Seybolt; Anthony Lehman
Journal:  Psychiatr Serv       Date:  2002-07       Impact factor: 3.084

9.  The epidemiology of multiple sclerosis in Devon: a comparison of the new and old classification criteria.

Authors:  C M Fox; S Bensa; I Bray; J P Zajicek
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-01       Impact factor: 10.154

10.  A comparison of the EQ-5D and SF-6D across seven patient groups.

Authors:  John Brazier; Jennifer Roberts; Aki Tsuchiya; Jan Busschbach
Journal:  Health Econ       Date:  2004-09       Impact factor: 3.046

View more
  37 in total

1.  The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.

Authors:  Jasmina I Ivanova; Howard G Birnbaum; Seth Samuels; Matthew Davis; Amy L Phillips; Dennis Meletiche
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

2.  Change in the Health-Related Quality of Life of Multiple Sclerosis Patients over 5 Years.

Authors:  Wonita Janzen; Karen V L Turpin; Sharon A Warren; Ruth Ann Marrie; Kenneth G Warren
Journal:  Int J MS Care       Date:  2013

3.  Comorbidity increases the risk of hospitalizations in multiple sclerosis.

Authors:  Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; Aruni Tennakoon; Nancy Yu
Journal:  Neurology       Date:  2014-12-24       Impact factor: 9.910

4.  Burden of a multiple sclerosis relapse: the patient's perspective.

Authors:  Merrikay Oleen-Burkey; Jane Castelli-Haley; Maureen J Lage; Kenneth P Johnson
Journal:  Patient       Date:  2012       Impact factor: 3.883

5.  Multiple sclerosis: relapses, resource use, and costs.

Authors:  A J Hawton; C Green
Journal:  Eur J Health Econ       Date:  2015-10-05

Review 6.  Pharmacoeconomic considerations in the treatment of multiple sclerosis.

Authors:  Jessica Sharac; Paul McCrone; Ramon Sabes-Figuera
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

7.  Intensive care unit admission in multiple sclerosis: increased incidence and increased mortality.

Authors:  Ruth Ann Marrie; Charles N Bernstein; Christine A Peschken; Carol A Hitchon; Hui Chen; Randy Fransoo; Allan Garland
Journal:  Neurology       Date:  2014-05-07       Impact factor: 9.910

8.  Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).

Authors:  Uwe K Zettl; Thomas Henze; Ute Essner; Peter Flachenecker
Journal:  Eur J Health Econ       Date:  2013-12-01

9.  Dramatically changing rates and reasons for hospitalization in multiple sclerosis.

Authors:  Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; James Blanchard; Aruni Tennakoon; Nancy Yu
Journal:  Neurology       Date:  2014-08-01       Impact factor: 9.910

10.  Validity and Reliability of the Greek Version of the Multiple Sclerosis International Quality-of-Life Questionnaire.

Authors:  Nikos Triantafyllou; Aris Triantafillou; Georgios Tsivgoulis
Journal:  J Clin Neurol       Date:  2009-12-31       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.